Number among 77 RA patients with physician estimates of % inflammation, % damage and % distress (total=100%) in clinical management decisions (% is of all patients) Background: Standard treatment of patients with rheumatoid arthritis (RA) complicated with pulmonary involvements has not been clarified. Objectives: To evaluate the influence of pulmonary involvement on immunological background and treatment of patients with RA. Methods: A cross-sectional study was conducted, in which medical records of 479 RA patients who visited our hospital during September the first to November 31th, 2016 were reviewed. Pulmonary involvements were diagnosed by imaging including plain chest radiography or chest computed tomography findings. Patients were divided into two groups, with or without pulmonary involvement, and compared with immunological background (serum level of rheumatoid factor (RF), anti-CCP antibody and recent treatment. Results: Among 479 patients, pulmonary involvements were diagnosed in 158 patients (female =116), mean age was 73.4 (standard deviation (SD) 9.0) year old, and mean disease duration was 143.3 (SD 125.9) months. Pulmonary involvements included interstitial pneumonia (N=52), organizing pneumonia (N=11), airway diseases (N=36), old tuberculosis (N=18), nontuberculous mycobacteria (N=13), pleurisy (N=5). Higher anti-CCP titers were found in RA with pulmonary involvement than RA only (medians 303.9±596.5 versus 163.5±256.1 U/mL, P<0.001), and the same result was found in RF (medians 322.5±437.2 versus 157.9±277.5 IU/mL, P<0.001). Methotrexate (MTX) was less frequently used (N=56, 35.4% versus N=205, 63.9%, P<0.001), but biological agents were more used (N=31, 19.6% versus N=49, 15.3%), especially abatacept (ABT) was highly used (N=15, 9.5% versus N=8, 2.5%). Conclusions: RA patients with pulmonary involvements had high immunological response and were less prescribed MTX with may injure lungs and more used ABT. Association between pulmonary involvement and high titer of ACPA, and between positivity for RF or ACPA and good response of ABT were reported. ABT may be useful treatment for RA patients with pulmonary involvement. Background: Bronchial obstruction (BO) is a common manifestation of lung involvement in rheumatoid arthritis (RA) with high incidence from 60 to 80% of all cases. However the pathogenesis of BO in patients with RA remains unknown. Serum level of protein CC16 produced by Clara cells in terminal bronchioles has been reported to decrease in BO associated with bronchial asthma, chronic obstructive pulmonary disease and others. CC16 was considered to demonstrate anti-inflammatory effect via inhibition of interferon-gamma, tumor necrosis factor alpha, interleukin 1 beta, neutrophil elastase and other proinflammatory factors. Also it was shown that CC16 deficiency has a pathogenic effect in BO. In the same time the role of protein CC16 in the pathogenesis of autoimmune diseases (and RA) is not studied. Objectives: We aimed to evaluate serum level of CC16 in patients with RA in dependence on the presence and severity of BO. Methods: Serum levels of CC16 in 66 patients with RA and 13 healthy controls were measured by enzyme linked immunoadsorbent assay (ELISA). Patients with RA underwent survey, physical examination and pulmonary function tests (PFTs) including spirometry and bronchodilator test with inhalation of salbutamol (N=41) and body plethysmography (N=11). Statistical processing was carried out using Spearman correlation coefficient and Mann-Whitney test. P value <0.05 was considered as significant. Results: More than 60% of participants with RA had BO in terminal bronchioles (small airway obstruction), which was revealed with changes of expiratory flows (forced expiratory volume in 1s (FEV1), forced expiratory flow (FEF) between 50% and 75% of forced vital capacity), residual volume (RV) and bronchial resistance (SGaw) in relation to proper values. Depression of post-bronchodilator FEF 75% lower than 70% was adopted as the main criterion of BO. There were no differences (p value >0,05) between serum levels of CC16 in patients with RA (20,14±1,49 ng/ml) and control group (22,70±2,13 ng/ml). However in patient group those with BO had significantly lower levels of CC16 (15 Objectives: To quantify at baseline and 3 years later, the prevalence (at baseline) and incidence (over 3 years) of some selected comorbidities.
Methods:
This was an open long term (3 years) extension of the COMEDRA 6-month randomized controlled trial in which patients with definite, stable RA were visiting a nurse for comorbidity counselling.
[2] Comorbidity status was assessed through face-to-face interviews and nurses provided advice on screening and management, at baseline and 3 years later. The frequency of comorbidities was assessed at both timepoints and incidence of new cases was assessed as overall % of patients and as relative increase in the given comorbidity. Results: Of the 970 recruited patients, 776 (80%) were followed up at 2-4 years (15, 1.5%, had died) and 769 (79%) had available data for comorbidities at both timepoints: at baseline, mean (±SD) age 58 (±11) years, mean disease duration 14 (±10) years; 614 (80%) were women and 538 (70%) were receiving a biologic with a mean DAS28 of 3.1±1.3. At baseline, the most frequent comorbidities were history of fracture (31.9%) and high blood pressure (30.9%) and at 3 years the comorbidity which had most increased (i.e., incidence) in this population aged around 60 years, was high blood pressure (4%) whereas smoking had decreased (Table) .
Conclusions:
Comorbidities are frequent in RA though screening does not always address the most frequent or severe comorbidities. Efforts must be pursued to improve comorbidity screening and prevention. Background: N-terminal pro-brain natriuretic peptide (NT-proBNP) is a recognized myocardial injure marker, a known predictor of heart failure and cardiovascular death. Rheumatoid arthritis (RA) patients (pts) were shown to have higher than in general population NT-proBNP concentrations, positively correlating with IL-6 levels. Adipose tissue is considered be one of the sources of this pro-inflammatory cytokine. But on the other hand, metabolic syndrome (MS) and obesity, which also occur in RA pts, are usually associated with lower NT-proBNP levels in general population. Objectives: To find out whether overweight/obesity or MS may modify NT-proBNP levels in RA pts. Methods: A total of 68 early RA pts (72% females, 28% males) was enrolled in the study. Mean disease duration was 6 [4;8] months, and RA activity using DAS28 calculator was 5,6 [5,1;6,4] scores. The majority of pts had positive RF (87%) and ACPA (88%). All pts were glucocorticoids and disease-modifying antirheumatic drugs -naïve prior to inclusion. The overweight/obesity was determined by WHO criteria in patients with body mass index (BMI) ≥25 kg/m 2 . National Cholesterol Education Program/Adult Treatment Panel III criteria were used to confirm MS. Serum levels of NT-proBNP (pg/mL) were measured using electrochemiluminescence test Elecsys proBNP II (Roche Diagnostics, Switzerland). NT-proBNP levels >125,0 pg/mL were considered as elevated. Results: Overweight and obesity were established in 54,4% RA pts. Overweight/obese RA pts were older than pts with normal BMI (57 [53; 61] years vs 48 [34; 61] years, p=0,02), had higher DAS28 scores (5, 85 [5, 20; 6, 57] vs 5, 28 [4, 76; 5, 69], p<0, 01), higher CRP (38, 8 [14, 3; 47, 9] mg/L vs 12, 8 [2, 2; 28, 8] mg/L, p<0,01). Elevated NT-proBNP concentrations were found in 62,2% overweight/obese pts vs 29,0% pts with normal weight (p<0,01), median NT-proBNP concentrations were 153,4 [87,3;236,9] pg/mL vs 75,2 [40,2;147,4] pg/mL, respectively (p=0,02). MS was established in 62,2% pts with BMI ≥25kg/m 2 and in 25,8% pts with BMI<25kg/m 2 (p<0,01). Median NT-proBNP concentrations did not vary significantly in pts with and without MS, whether they were overweight/obese (p=0,75), or had normal BMI (p=0,27). Although higher rates of elevated NT-proBNP concentrations were documented in pts with MS (61, 3% vs 35, 1%, p=0, 03) . NT-proBNP levels positively correlated with waist circumference (r=0,33, p<0,01) , ESR (r=0, 25, p=0, 04), and CRP (r=0, 3, p=0, 01) . Conclusions: Overweight and obesity in RA pts were associated with increased NT-proBNP levels. Abdominal obesity was identified as the only MS component, influencing NT-proBNP levels, presumably via up-regulation of the inflammatory process. Objectives: To assess the effectiveness of our CV risk management program after one year. Methods: CV risk screening was performed at baseline and we informed the general practitioner (GP) about the results, including advices regarding the initiation of cardio preventive drugs. In high risk patients, antihypertensives were recommended when systolic blood pressure >140 mm/Hg and statins were recommended when low-density lipoprotein >2.5 mmol/l. The decision to start preventive medication was left to the GP. CV risk screening was repeated after one year. Patients completed a questionnaire about the actions that were taken following the results of the initial screening. Results: Of the 266 patients 202 (76%) were female, the mean age was 58±11 years. After one year, 88 out of 134 patients who received inadequate or no treatment at baseline were still untreated or undertreated. Of the 188 (71%) patients who were at high CV risk and who did have an indication to start therapy, only 7.5% was contacted by their GP and another 6.8% arranged an appointment themselves. While the 10-year CV risk did not decrease in the group as a whole, a risk reduction was found in the patients that started medication. Remarkably, 42% of patients reported lifestyle changes, including more exercise (20%), diet adaption (16%) and weight loss (9%). Conclusions: It is striking that one year after the introduction of our CV risk
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